

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <b>MURPHY ANDREW J</b> (Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD (Street) TARRYTOWN NY 10591 (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <b>REGENERON PHARMACEUTICALS, INC. [ REGN ]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) <b>EVP Research</b>		
			3. Date of Earliest Transaction (Month/Day/Year) <b>03/13/2024</b>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
			4. If Amendment, Date of Original Filed (Month/Day/Year)			Rule 10b5-1(c) Transaction Indication <input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/13/2024		M <sup>(1)</sup>		20,000	A	\$399.66	68,306	D	
Common Stock	03/13/2024		F <sup>(1)</sup>		14,217	D	\$971.82	54,089	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		182	D	\$951.92 <sup>(2)</sup>	53,907	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		444	D	\$952.4 <sup>(3)</sup>	53,463	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		576	D	\$953.77 <sup>(4)</sup>	52,887	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		870	D	\$954.66 <sup>(5)</sup>	52,017	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		545	D	\$955.54 <sup>(6)</sup>	51,472	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		1,108	D	\$956.34 <sup>(7)</sup>	50,364	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		730	D	\$957.35 <sup>(8)</sup>	49,634	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		477	D	\$958.34 <sup>(9)</sup>	49,157	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		512	D	\$959.36 <sup>(10)</sup>	48,645	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		47	D	\$961.74	48,598	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		1	D	\$962.87	48,597	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		78	D	\$965.51 <sup>(11)</sup>	48,519	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		17	D	\$966.3	48,502	D	
Common Stock	03/14/2024		S <sup>(1)</sup>		196	D	\$968.2 <sup>(12)</sup>	48,306	D	
Common Stock								4,310	I	By 401(k) Plan

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Non-Qualified Stock Option (right to buy)	\$399.66	03/13/2024		M <sup>(1)</sup>			20,000	(13)	12/16/2024	Common Stock	20,000	\$0.0	20,000	D	

**Explanation of Responses:**

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 9, 2023.

2. Represents volume-weighted average price of sales of 182 shares of Company stock on March 14, 2024 at prices ranging from \$951.89 to \$951.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
3. Represents volume-weighted average price of sales of 444 shares of Company stock on March 14, 2024 at prices ranging from \$952.00 to \$952.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
4. Represents volume-weighted average price of sales of 576 shares of Company stock on March 14, 2024 at prices ranging from \$953.30 to \$953.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
5. Represents volume-weighted average price of sales of 870 shares of Company stock on March 14, 2024 at prices ranging from \$954.01 to \$954.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
6. Represents volume-weighted average price of sales of 545 shares of Company stock on March 14, 2024 at prices ranging from \$955.02 to \$955.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
7. Represents volume-weighted average price of sales of 1,108 shares of Company stock on March 14, 2024 at prices ranging from \$956.08 to \$956.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
8. Represents volume-weighted average price of sales of 730 shares of Company stock on March 14, 2024 at prices ranging from \$957.02 to \$957.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
9. Represents volume-weighted average price of sales of 477 shares of Company stock on March 14, 2024 at prices ranging from \$958.06 to \$958.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
10. Represents volume-weighted average price of sales of 512 shares of Company stock on March 14, 2024 at prices ranging from \$959.13 to \$959.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
11. Represents volume-weighted average price of sales of 78 shares of Company stock on March 14, 2024 at prices ranging from \$965.26 to \$965.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
12. Represents volume-weighted average price of sales of 196 shares of Company stock on March 14, 2024 at prices ranging from \$968.15 to \$968.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 14, 2024 at each separate price.
13. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

/s/\*\*Andrew Murphy

03/15/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**